Integra LifeSciences Holdings Corporation (IART) Getting Somewhat Positive News Coverage, Study Shows

Media headlines about Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Integra LifeSciences Holdings Corporation earned a news impact score of 0.20 on Accern’s scale. Accern also assigned media coverage about the life sciences company an impact score of 44.8630438741252 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Integra LifeSciences Holdings Corporation (IART) opened at 48.31 on Friday. The firm has a 50-day moving average of $50.51 and a 200-day moving average of $48.58. The stock has a market cap of $3.77 billion, a PE ratio of 58.91 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.45. The firm had revenue of $282.16 million for the quarter, compared to analysts’ expectations of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.40 earnings per share. Analysts expect that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current fiscal year.

Several brokerages recently commented on IART. UBS AG reaffirmed a “buy” rating and set a $60.00 price objective (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Friday, June 9th. Oppenheimer Holdings, Inc. set a $60.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald began coverage on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday, June 29th. They set an “overweight” rating and a $65.00 price objective for the company. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Raymond James Financial, Inc. boosted their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation currently has a consensus rating of “Buy” and an average target price of $53.54.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/09/22/integra-lifesciences-holdings-corporation-iart-getting-somewhat-positive-news-coverage-study-shows.html.

In related news, Director Barbara B. Hill acquired 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Tuesday, August 1st. The shares were purchased at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the transaction, the director now directly owns 44,772 shares in the company, valued at approximately $2,208,602.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Friday, August 4th. The shares were bought at an average price of $49.25 per share, for a total transaction of $492,500.00. Following the transaction, the director now owns 29,612 shares of the company’s stock, valued at $1,458,391. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 17,550 shares of company stock worth $864,842. Company insiders own 21.50% of the company’s stock.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply